Bordeaux, Boston, April 11, 2023 – 7:30 a.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the distribution of technological medical equipment, today announced the approval by the Food and Drug Administration (FDA) of its SqualeTM anterior cervical cage.
Ludovic Lastennet, Managing Director of IMPLANET, declares: “This new certification once again demonstrates the full potential of the synergies offered to us by the range of products from the OSD portfolio and is fully in line with our strategy aimed at boosting our presence in the USA. Implanet America’s sales teams should therefore be able to launch the marketing of this range of anterior cervical cages before the summer of 2023. This is a new structuring step for our development plan in the United States, aiming in particular to consolidate our offer in the field of spinal surgery on a market estimated at 1.35 billion dollars. ยป
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]